# GLP-1 Drugs and Mortality in Type 2 Diabetes With a BMI Under 27 | This GLP In adults with type 2 diabetes and BMI under 27, GLP-1 drugs showed mortality HR 0.61 against DPP-4 inhibitors and 0.89 against SGLT2 inhibitors. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-mortality-authors-doubt-their-own Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs and Mortality in Type 2 Diabetes With a BMI Under 27 A study found 39% lower all-cause mortality on GLP-1 drugs, then said in its conclusion that the number is probably confounding rather than benefit. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Hazard ratios, BMI under 27 with type 2 diabetes · vs DPP-4i · death, any cause · 0.61 · vs SGLT2i · death, any cause · 0.89 · vs DPP-4i · coded heart failure · 0.71 · vs SGLT2i · coded heart failure · 0.56 · The mortality benefit disappears against the stronger comparator. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Adults with type 2 diabetes and a body mass index under 27 — the group the weight trials exclude. - Against DPP-4 inhibitors, GLP-1 drugs were linked to 39% lower all-cause mortality, hazard ratio 0.61, 95% CI 0.52 to 0.71. - Against SGLT2 inhibitors, mortality did not differ: 0.89, 95% CI 0.76 to 1.05. - Coded heart failure was lower across all three comparisons — the authors' own most consistent finding. - The authors say the mortality result likely reflects residual confounding rather than a benefit of that size. A 39% reduction in death from any cause is the kind of number that ends up in a headline, and the people who calculated it wrote a sentence asking you not to treat it that way. It is worth understanding why they did, because the reasoning is visible inside their own results — the same kind of internal check as [a comparison run where a difference is expected](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). ## Who was studied Adults with type 2 diabetes and a body mass index below 27, starting a GLP-1 drug, compared separately against new users of DPP-4 inhibitors, SGLT2 inhibitors and usual care. [\[1\]](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own#ref-1) Matching left 7,389, 8,969 and 8,610 GLP-1 users in the three comparisons, followed up to 24 months. That population is the reason the study exists. The cardiovascular evidence for these drugs comes almost entirely from trials in people with overweight or obesity, and a person with diabetes and a body mass index of 25 has been largely absent from it — the same gap between a trial population and a treated one that [eligibility figures](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) keep exposing. ## What the three comparisons gave Against DPP-4 inhibitors: all-cause mortality 0.61, 95% CI 0.52 to 0.71. Major adverse cardiovascular events 0.83, 95% CI 0.71 to 0.98. Coded heart failure 0.71, 95% CI 0.60 to 0.85. Against SGLT2 inhibitors: cardiovascular events 0.81, 95% CI 0.69 to 0.95, and coded heart failure 0.56, 95% CI 0.47 to 0.65 — but all-cause mortality 0.89, 95% CI 0.76 to 1.05, which crosses one. Why that pattern is the tell SGLT2 inhibitors are an active comparator with a mortality benefit of their own, so a drug effect would not be expected to disappear entirely against them — it might shrink. A confounding effect behaves differently: if the people started on a GLP-1 are systematically healthier or better cared for than the people started on a DPP-4 inhibitor or left on usual care, the gap will be largest against the weakest comparator and smallest against the one prescribed to a similar population. That is what happened, and it is why the authors describe a 39% mortality reduction as likely residual confounding rather than a benefit of that magnitude. ## What they do stand behind Coded heart failure, which was lower across all three comparisons. That consistency is the thing a confounding explanation has more trouble with, and it is what the authors present as their most reliable result. It is still a coded event — a diagnosis appearing in a record rather than an adjudicated one — so it carries the same caveat as [any outcome assembled from what somebody wrote down](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs). ## And a harm in the same study Gastroparesis was more frequent on GLP-1 drugs than on DPP-4 inhibitors. Slowed stomach emptying is the mechanism these drugs work partly through, so a rise in its clinical extreme is coherent rather than surprising, and it belongs in the same summary as the benefits — alongside [what is already known about that](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## What a reader takes from it Not a result about weight-loss buyers. Everybody here had type 2 diabetes and a body mass index under 27, which is nobody this site’s sellers are writing prescriptions for. What travels is the method: when an observational result is huge against a weak comparator and gone against a strong one, the comparator is doing the work. Authors who say so about their own headline are rarer than the finding. ## Frequently asked Do GLP-1 drugs reduce death in people who are not overweight? This study found a hazard ratio of 0.61 against DPP-4 inhibitors, and the authors state that result likely reflects residual confounding rather than a benefit of that size. Why does the SGLT2 comparison matter? Because mortality did not differ against it, 0.89, 95% CI 0.76 to 1.05. A real drug effect would be expected to shrink rather than disappear; confounding produces exactly this pattern. What result do the authors stand behind? Lower coded heart failure, which was consistent across all three comparisons. Consistency is harder for a confounding explanation to account for. Was anything worse? Gastroparesis was more frequent on GLP-1 drugs than on DPP-4 inhibitors in the same analysis. ## Sources 1. \[1\] Chen SC, et al. (2026). Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation Diabetes, Obesity and Metabolism. [PMID 42642357](https://pubmed.ncbi.nlm.nih.gov/42642357/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)